Logo for Theseus Pharmaceuticals Inc

Theseus Pharmaceuticals Investor Relations Material

Latest events

Logo for Theseus Pharmaceuticals Inc

Status Update

Theseus Pharmaceuticals
Logo for Theseus Pharmaceuticals

Q3 2023

17 Nov, 2023
Logo for Theseus Pharmaceuticals

Q2 2023

11 Aug, 2023
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies

Latest reports from Theseus Pharmaceuticals Inc

Access all reports
Theseus Pharmaceuticals Inc., trading under the NASDAQ symbol THRX, is a biopharmaceutical company dedicated to the discovery, development, and commercialization of targeted therapies for cancer patients. The company's leading product candidate is THE-630, a pan-KIT inhibitor aimed at treating gastrointestinal stromal tumors. Additionally, Theseus is developing THE-349, a fourth-generation selective epidermal growth factor receptor inhibitor intended for use in non-small cell lung cancer patients who have developed resistance to first- or later-line osimertinib treatment. The company is headquartered in Cambridge, Massachusetts, and its shares are listed on the Nasdaq.